Diprosone
Phase 2Small molecule
LEO PharmaDiprosone is one of 48 small molecule programs targeting Psoriasis Vulgaris. It is currently in Phase 2.
2
Indications
3
Total Trials
0
Active Trials
47
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
107 competitors in Psoriasis Vulgaris
#DrugCompanyPhaseTrials
1Cimzia
UCBPhase 3
Omvoh
Eli LillyPhase 3
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Sorilux
LEO PharmaPhase 3
Orencia
Bristol-Myers SquibbPhase 2
Trexall
Alnylam PharmaceuticalsPhase 2
Asmanex
NovartisPhase 2
LEO 43204
LEO PharmaPhase 2
Celestone
SSchering-Plough
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Psoriasis Vulgaris1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Diprosone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company